ClinicalTrials.gg
CompletedNCT02881294Updated Sep 25, 2017

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects

A Phase 1 interventional study of SUVN-G3031 in Cognitive Disorders, sponsored by Suven Life Sciences Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-25.

Sponsored by Suven Life Sciences Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,420 studies in Cognitive Dysfunction with a site in United States — 329 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Enrollment
861st of 1,145
24 · median 59
Started
2016
with 58 others
Phase 1
102 of 1,420
21 open now
Registered
428th of 1,420
by date

Among the 1,420 studies in Cognitive Dysfunction with a site in United States, this one is the 861st largest by enrollment of the 1,145 interventional ones that give a count, is one of 59 that started in 2016, is one of 102 in phase 1, and was the 428th registered.

Cognitive Dysfunction

3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

329 of the 1,420 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

324 more — sign in →

All 329 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,420 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects

03

Conditions studied

  • Cognitive Disorders
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female aged 18 to 45 years with a between 18 and 30 kg/m2, (inclusive) for food and gender effect
  • Healthy male aged 60 to 70 years with a BMI between 18 and 32 kg/m2, (inclusive) for age effect

Exclusion criteria

Exclusion Criteria:

  • History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs as judged by Investigator.
  • Any illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of the study drug.
  • Any positive result on screening for serum surface antigen (HBsAg), virus (HCV) antibody, and (HIV) antibody
  • History of any important clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Food Effect

    SUVN-G3031 tablets single dose

    Drug: SUVN-G3031

  • Active comparator
    Gender Effect

    SUVN-G3031 tablets single dose

    Drug: SUVN-G3031

  • Active comparator
    Age Effect

    SUVN-G3031 tablets single dose

    Drug: SUVN-G3031

Interventions

06

What researchers measure

Primary outcomes

  1. Area under concentration (AUC)

    Time frame: 96 hours

  2. Maximum observed concentration (Cmax)

    Time frame: Day 1

07

Study locations

1 site
  • Quintiles
    Overland Park, Kansas 66211, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Sep 2017, 13 months.

Of 26 industry-sponsored phase 1 interventional studies under Cognitive Dysfunction, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 40. This study's 13 months is below that.

Counting every sponsor, half of 80 studies reached it within 27 months; a quarter within 13 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2016
First posted
Aug 26, 2016
StartActual
Aug 2016
Primary completionActual
Sep 2017
CompletionActual
Sep 2017
Last update
Sep 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02881294
Lead sponsor
Suven Life Sciences Limited
Responsible party
Sponsor
First posted
Aug 26, 2016
Start date
Aug 2016
Primary completion
Sep 2017
Completion
Sep 2017
Last update
Sep 25, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Samelisant

Start the discussion